new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors




Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015023986608/27/15  new patent  Triazolyl derivatives as syk inhibitors
62015023242808/20/15 Substituted phenyl-spleen tyrosine kinase (syk) inhibitors
72015023244708/20/15 Crystalline form of a reverse transcriptase inhibitor
82015022536508/13/15 Indoline compounds as aldosterone synthase inhibitors
92015022540208/13/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
102015021809608/06/15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
112015021809708/06/15 Glycosidase inhibitors and uses thereof
122015021814708/06/15 Glycosidase inhibitors and uses thereof
132015021814908/06/15 Novel benzimidazole tetrahydrofuran derivatives
142015021816408/06/15 Substituted naphthyridinedione derivatives as hiv integrase inhibitors
152015021816908/06/15 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof
162015020942407/30/15 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
172015021068507/30/15 Novel azabenzimidazole tetrahydropyran derivatives
182015021068707/30/15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
192015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
202015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
212015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
222015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
232015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
242015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
252015019777207/16/15 Mammalian expression vector puhab
262015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
272015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
282015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
292015019149507/09/15 Antidiabetic tricyclic compounds
302015018250307/02/15 Mineralocorticoid receptor antagonists
312015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
322015017557506/25/15 Imidazolyl analogs as syk inhibitors
332015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
342015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
352015016649006/18/15 Mineralocorticoid receptor antagonists
362015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
372015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
382015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
392015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
402015014733705/28/15 Crystalline anti-human il-23 antibodies
412015014824605/28/15 Surface anchored light chain bait antibody display system
422015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
432015013998605/21/15 Ilt3 binding molecules and uses therefor
442015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
452015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
462015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
472015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
482015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
492015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
502015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
512015011191404/23/15 Spirolactam cgrp receptor antagonists
522015010445304/16/15 Fdf03 antibodies and uses thereof
532015010446504/16/15 Il-19 as a biomarker of tslp treatment
542015010531704/16/15 Glucose-responsive insulin conjugates
552015010535404/16/15 Heterocyclic aspartyl protease inhibitors
562015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
572015009971504/09/15 Formulations of acadesine
582015009971904/09/15 Cathepsin cysteine protease inhibitors
592015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
602015009977104/09/15 Pyridine cgrp receptor antagonists
612015009339804/02/15 Methods and compositions for treating or preventing cancer
622015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes
632015008764103/26/15 Heterocyclic cgrp receptor antagonists
642015008783203/26/15 Process for making beta 3 agonists and intermediates
652015007899603/19/15 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
662015007903103/19/15 Use of pegylated il-10 to treat cancer
672015008059803/19/15 Asymmetric synthesis for preparing fluoroleucine alkyl esters
682015006419203/05/15 Mammalian cell surface antigens; related reagents
692015005619102/26/15 Igf1 biomarker for igf1r inhibitor therapy
702015005122702/19/15 Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
712015005124802/19/15 Imidazolyl methyl piperidine t-type calcium channel antagonists
722015004425002/12/15 Vaccines against clostridium difficile comprising recombinant toxins
732015004534602/12/15 Selective glycosidase inhibitors and uses thereof
742015004557502/12/15 Process for preparing fluoroleucine alkyl esters
752015003849002/05/15 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
762015003849802/05/15 Thrombin inhibitors
772015003850202/05/15 Isoxazolopyridine orexin receptor antagonists
782015003870702/05/15 Process for making cgrp receptor antagonists
792015003171301/29/15 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
802015003171601/29/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
812015003189101/29/15 Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
822015002080601/22/15 Dry powder inhaler for delivering multipe agglomerate formulations
832015002395201/22/15 Anti-addl monoclonal antibody and uses thereof
842015002407101/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
852015002504601/22/15 Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
862015001768601/15/15 Methods for reducing mannosyltransferase activity in lower eukaryotes
872015001839901/15/15 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
882015001056401/08/15 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
892015000460801/01/15 Monocyte-derived nucleic acids and related compositions and methods
902015000533001/01/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
912014037726012/25/14 Protective vaccine based on staphylococcus aureus sa2074 protein
922014037849312/25/14 Fused bicyclic oxazolidinone cetp inhibitor
932014037002512/18/14 Uses of mammalian cytokines and agonists; related reagents
942014037113812/18/14 Inhibitors of hepatitis c virus replication
952014034997211/27/14 Substituted pyrimidines
962014034884111/27/14 Anti-gitr antibodies
972014034999811/27/14 Pyrrolopyrimidines as janus kinase inhiitors
982014035000211/27/14 Imidazopyridin-2-one derivatives
992014034307111/20/14 Compositions and methods for treating cancer
1002014033619611/13/14 Phosphoric acid salts of sitagliptin
1012014032927611/06/14 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
1022014032351910/30/14 Heterocyclic compounds as b-raf inhibitors for treatment of cancer
1032014029620210/02/14 Substituted piperidinyl compounds useful as gpr119 agonists
1042014029622110/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1052014029622210/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1062014027501709/18/14 Cgrp receptor antagonists
1072014025681809/11/14 Nano-suspension process
1082014024428908/28/14 Cold storage system for storing pharmaceutical product containers
1092014023429608/21/14 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
1102014023430108/21/14 Modulation of pilr to treat immune disorders
1112014023553708/21/14 N-glycosylated insulin analogues
1122014022562708/14/14 Device for calibrating and verifying the integrity of resistivity-based sensing probes
1132014022722308/14/14 Pegylated interleukin-10
1142014022725008/14/14 Stable formulations of antibodies to tslp
1152014022729008/14/14 Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
1162014022729208/14/14 Anti-mcam antibodies and associated methods of use
1172014022002708/07/14 1d05 pcsk9 antagonists
1182014022138308/07/14 Cetp inhibitors
1192014021241207/31/14 Use of il-33 antagonists to treat fibrotic disease
1202014020656307/24/14 Biomarkers for psoriasis
1212014020664007/24/14 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1222014020664107/24/14 Remedy
1232014020666507/24/14 Selective glycosidase inhibitors and uses thereof
1242014020667507/24/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1252014020671507/24/14 Preparation and use of compounds as protease inhibitors
1262014020018007/17/14 Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1272014020021307/17/14 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
1282014017015406/19/14 Engineered anti-il-23r antibodies
1292014017065806/19/14 Mammalian cytokines; related reagents
1302014017143706/19/14 Oxazole derivatives useful as inhibitors of faah
1312014017145606/19/14 Fused tricyclic compounds as mtor inhibitors
1322014017148006/19/14 Crystalline polymorphic forms of an antidiabetic compound
1332014016177006/12/14 2'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
1342014016179806/12/14 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
1352014014744205/29/14 Use of il-23 antagonists for treatment of infection
1362014014746105/29/14 Polypeptides for inducing a protective immune response against staphylococcus aureus
1372014014095405/22/14 Methods of modulating cytokine activity; related reagents
1382014014101205/22/14 Engineered anti-tslp antibody
1392014014144405/22/14 Isolated mammalian monocyte cell genes; related reagents
1402014014144505/22/14 Isolated mammalian monocyte cell genes; related reagents
1412014014211505/22/14 Inhibitors of the renal outer medullary potassium channel
1422014012836105/08/14 Cyclic amide bace-1 inhibitors having a benzamide substituent
1432014012836705/08/14 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
1442014012836805/08/14 Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
1452014012003705/01/14 Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
1462014011291904/24/14 Interleukin-10 antibodies
1472014011392004/24/14 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1482014010588704/17/14 Methods for modulating il-33 activity
1492014010641304/17/14 Immobilized transaminases and process for making and using immobilized transaminase
1502014010734604/17/14 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
1512014009356404/03/14 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
1522014009387504/03/14 Mammalian cytokines; receptors; related reagents and methods
1532014008804803/27/14 Diazeniumdiolate cyclohexyl derivatives
1542014008088403/20/14 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
1552014005789302/27/14 Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
1562014005174002/20/14 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1572014004574602/13/14 Antidiabetic tricyclic compounds
1582014004582902/13/14 Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1592014004583202/13/14 Insulin-like growth factor-1 receptor inhibitors
1602014003762702/06/14 Modulation of pilr receptors to treat microbial infections
1612014003894202/06/14 Rorgammat inhibitors
1622014003897002/06/14 Bridged and fused antidiabetic compounds
1632014003025501/30/14 Methods of predicting cancer cell response to therapeutic agents
1642014003076001/30/14 Pavec
1652014003125101/30/14 Methods of classifying human subjects with regard to cancer prognosis
1662014003134901/30/14 Inhibitors of the renal outer medullary potassium channel
1672014002366701/23/14 Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1682014000518201/02/14 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1692013034451212/26/13 Cd16a reporter assay for evaluation of adcc potential of biologics
1702013033137212/12/13 Cyclic amine substituted oxazolidinone cetp inhibitor
1712013032323912/05/13 Modulation of pilr receptors to treat sepsis
1722013032324612/05/13 Use of mdl-1 antagonists to treat spondylarthropathy
1732013032325112/05/13 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1742013032448312/05/13 Mammalian cell surface antigens; related reagents
1752013032461012/05/13 Cathepsin cysteine protease inhibitors
1762013032472812/05/13 Process for the preparation of an orexin receptor antagonist
1772013031635411/28/13 Mammalian cytokine; related reagents
1782013029627811/07/13 Diazeniumdiolate derivatives
1792013028776310/31/13 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1802013028021410/24/13 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1812013028147410/24/13 Fused tricyclic inhibitors of mammalian target of rapamycin
1822013026114010/03/13 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1832013025167709/26/13 Genetic markers associated with interferon-alpha response
1842013024369209/19/13 Fdg-pet evaluation of ewing's sarcoma sensitivity
1852013023751809/12/13 Novel compounds that are erk inhibitors
1862013023085509/05/13 Monocyte-derived nucleic acids and related compositions and methods
1872013022558208/29/13 Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1882013022583608/29/13 Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1892013021657508/22/13 Recombinant subunit dengue virus vaccine
1902013021769508/22/13 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1912013021775608/22/13 Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1922013021776608/22/13 Formulations for cathepsin k inhibitors
1932013020306008/08/13 Mammalian genes; related reagents
1942013018927807/25/13 Antagonists of pcsk9
1952013015794006/20/13 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1962013015672906/20/13 Mammalian receptor proteins; related reagents and methods
1972013015677106/20/13 Fdf03 antibodies and uses thereof
1982013015036206/13/13 Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1992013014385906/06/13 Novel prolylcarboxypeptidase inhibitors
2002013013104105/23/13 Spirocyclic compounds
2012013013104205/23/13 Spiroxazolidinone compounds
2022013012200905/16/13 Engineered anti-il-23p19 antibodies
2032013012320005/16/13 Mammalian cell surface antigens; related reagents
2042013012323705/16/13 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2052013011522305/09/13 Antagonists of pcsk9
2062013011623105/09/13 Tyrosine kinase inhibitors
2072013010973905/02/13 Compositions and methods for short interfering nucleic acid inhibition of nav1.8
2082013009605304/18/13 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
2092013007139003/21/13 Method for preparing antibodies having improved properties
2102013006481703/14/13 Engineered anti-il-23r antibodies
2112013005985003/07/13 Aza-indole derivatives useful as modulators of faah
2122013005335202/28/13 Diazeniumdiolate cyclopentyl derivatives
2132013004591402/21/13 Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
2142013004092902/14/13 Novel prolylcarboxypeptidase inhibitors
2152013004093202/14/13 Substituted aryl sulfone derivatives as calcium channel blockers
2162013003456102/07/13 Isolated mammalian monocyte cell genes; related reagents
2172013003531202/07/13 Cathepsin cysteine protease inhibiors
2182013002351501/24/13 Novel spiropiperidine prolylcarboxypeptidase inhibitors
2192013001804801/17/13 Oxazole derivatives useful as modulators of faah
2202013001252601/10/13 Oxazole derivatives useful as modulators of faah
2212013000579701/03/13 Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
2222013000451801/03/13 Cyclic amine bace-1 inhibitors having a benzamide substituent
2232012032967912/27/12 Eukaryotic cell display systems
2242012031532112/13/12 Immunological methods and compositions for the treatment of alzheimer's disease
2252012031620012/13/12 Pyridone derivatives
2262012027724011/01/12 Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2272012026477710/18/12 Oxadiazole beta carboline derivatives as antidiabetic compounds
2282012023200709/13/12 Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
2292012023208609/13/12 Fused tricyclic compounds with adenosine a2a receptor antagonist activity
2302012022588609/06/12 Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2312012021484608/23/12 Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2322012021484708/23/12 2-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
2332012020188508/09/12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
2342012019690108/02/12 Tertiary amide orexin receptor antagonists
2352012019070107/26/12 Renin inhibitors
2362012017868107/12/12 Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
2372012017875007/12/12 Niacin receptor agonists, compositions containing such compounds and methods of treatment
2382012017239707/05/12 Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2392012016415806/28/12 Anti-addl monoclonal antibody and use thereof
2402012015743806/21/12 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2412012015743206/21/12 Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2422012014277006/07/12 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
2432012014269406/07/12 Substituted 4-hydroxypyrimidine-5-carboxamides
2442012014275206/07/12 Hiv protease inhibitors
2452012013601205/31/12 Amino tetrahydro-pyridopyrimidine pde10 inhibitors
2462012012162405/17/12 Hepatitis c virus ns3 protease inhibitors
2472012011913005/17/12 Diaphragm valve with improved sealing performance and leak detection
2482012012150805/17/12 Radiolabeled cgrp antagonists
2492012012158005/17/12 Methods for producing high concentration lyophilized pharmaceutical formulations



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE